$KOD:NASDAQ - KODIAK SCIENCES - Up 950% over 12 months

Kodiak has had an amazing run over the last year but has been ranging sideways for the last couple of months. With a Bollinger breakout to the upside it could be worth a look.

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD.